Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2020-10-27
Original market date: See footnote 1
2020-10-27
Product name:
OSNUVO
DIN:
02495589
Product Monograph/Veterinary Labelling:
Date:
2022-03-14
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
AVIR PHARMA INC.
660 Boulevard Industriel
Blainville
Quebec
Canada
J7C 3V4
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Subcutaneous
Number of active ingredient(s):
1
Schedule(s):
Prescription , Schedule D
Biosimilar Biologic Drug:
Yes
American Hospital Formulary Service (AHFS): See footnote 3
92:22.00 , 68:24.08
Anatomical Therapeutic Chemical (ATC): See footnote 4
H05AA02 TERIPARATIDE
Active ingredient group (AIG) number:See footnote5
0150152001
| Active ingredient(s) | Strength |
|---|---|
| TERIPARATIDE | 250 MCG / ML |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.